Creative Medical Technology Announces Public Offering of Shares & Warrants
Creative Medical Technology Holdings, Inc. is launching a best efforts public offering of up to 3,045,685 shares of common stock, along with public warrants to purchase up to 6,091,371 shares and pre-funded warrants for up to 3,045,685 shares, at an assumed price of $1.97 per unit. The offering aims to raise approximately $5.34 million in net proceeds to fund ongoing clinical trials for chronic lower back pain and Type 1 Diabetes, develop its iPSCelz™ program, and for general corporate purposes. The company has recently achieved several clinical and regulatory milestones, including FDA Fast Track designation for CELZ-201-DDT and Orphan Drug Designation for ImmCelz™ (CELZ-100). However, the filing highlights significant risks, potential dilution, and the best efforts nature of the offering.
Key Highlights
- Offering up to 3,045,685 common shares and 6,091,371 public warrants.
- Includes pre-funded warrants for up to 3,045,685 shares.
- Assumed public offering price of $1.97 per share and accompanying Public Warrants.
- Estimated net proceeds of approximately $5.34 million from the offering.
- Proceeds to fund clinical trials for chronic lower back pain and Type 1 Diabetes.
- FDA granted Fast Track designation for CELZ-201-DDT in August 2025.
- FDA granted Orphan Drug Designation for ImmCelz™ (CELZ-100) in March 2024.
- Completed patient enrollment for ADAPT clinical trial in December 2025.
Price Impact
More from CELZ